Scientific Committee on Consumer Products

SCCP

OPINION ON

Vitamin K1
(Phytonadione)

The SCCP adopted this opinion at its 16th plenary of 24 June 2008
About the Scientific Committees

Three independent non-food Scientific Committees provide the Commission with the scientific advice it needs when preparing policy and proposals relating to consumer safety, public health and the environment. The Committees also draw the Commission's attention to the new or emerging problems which may pose an actual or potential threat.

They are: the Scientific Committee on Consumer Products (SCCP), the Scientific Committee on Health and Environmental Risks (SCHER) and the Scientific Committee on Emerging and Newly Identified Health Risks (SCENIHR) and are made up of external experts.

In addition, the Commission relies upon the work of the European Food Safety Authority (EFSA), the European Medicines Evaluation Agency (EMEA), the European Centre for Disease prevention and Control (ECDC) and the European Chemicals Agency (ECHA).

SCCP

Questions concerning the safety of consumer products (non-food products intended for the consumer).

In particular, the Committee addresses questions related to the safety and allergenic properties of cosmetic products and ingredients with respect to their impact on consumer health, toys, textiles, clothing, personal care products, domestic products such as detergents and consumer services such as tattooing.

Scientific Committee members

Claire Chambers, Gisela Degen, Ruta Dubakiene, Bozena Jazwiec-Kanyion, Vassilios Kapoulas, Jean Krutmann, Carola Lidén, Jean-Paul Marty, Thomas Platzek, Suresh Chandra Rastogi, Jean Revuz, Vera Rogiers, Tore Sanner, Günter Speit, Jacqueline Van Engelen, Ian R. White

Contact

European Commission
Health & Consumer Protection DG
Directorate C: Public Health and Risk Assessment
Unit C7 - Risk Assessment
Office: B232 B-1049 Brussels
Sanco-Sc6-Secretariat@ec.europa.eu

© European Commission 2008

The opinions of the Scientific Committees present the views of the independent scientists who are members of the committees. They do not necessarily reflect the views of the European Commission. The opinions are published by the European Commission in their original language only.

ACKNOWLEDGMENTS

Dr. C. Chambers
Prof. G. Degen
Dr. B. Jazwiec-Kanyion
Prof. V. Kapoulas
Prof. J.-P. Marty
Prof. T. Platzek
Dr. S.C. Rastogi
Prof. J. Revuz (rapporteur)
Prof. V. Rogiers
Prof. T. Sanner (chairman)
Dr. J. van Engelen
Dr. I.R. White

Keywords: SCCP, scientific opinion, vitamin K1, directive 76/768/ECC, CAS 84-80-0 (phytomenadione), 11104-38-4 (vitamin K1), EINECS 201-564-2 (phytomenadione), 234-330-3 (vitamin K1)

Opinion to be cited as: SCCP (Scientific Committee on Consumer Products), Opinion on vitamin K1, 24 June 2008
# TABLE OF CONTENTS

ACKNOWLEDGMENTS ............................................................................................................. 3

1. BACKGROUND .................................................................................................................... 5

2. TERMS OF REFERENCE ..................................................................................................... 5

3. OPINION .............................................................................................................................. 6

4. CONCLUSION ..................................................................................................................... 18

5. MINORITY OPINION ......................................................................................................... 18

6. REFERENCES ...................................................................................................................... 18
1. BACKGROUND

A scientific opinion has recently been adopted by written procedure on 28 September 2007 by the SCCP on vitamin K1 (SCCP/1105/07) with the following conclusion:

"Because of the inadequate nature of the dossier submitted, the SCCP is unable to provide an adequate safety evaluation for the use of vitamin K1 (phytonadione) and its "oxide" in cosmetic products. However, as such use may cause cutaneous allergy, individuals so affected may be denied an important therapeutic agent."

A complete dossier was submitted by November 2007.

According to the applicant the vitamin K1 with the CAS 81818-54-4 and EINECS 279-833-9 and the chemical name 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone is safe to be used in cosmetic products up to a maximum concentration of 1.0%.

2. TERMS OF REFERENCE

1. Does the SCCP consider that the concern by this substance in a concentration up 1.0% to cause allergy is superseded by the scientific data submitted?

2. If yes, does the SCCP consider that vitamin K1 is safe when used in cosmetic product in a concentration up to 1%?
3. OPINION

3.1. Chemical and Physical Specifications

The dossier submitted contained data on several toxicological endpoints. Since the Member State notification which initially triggered the safety evaluation of Vitamin K1 concerned the sensitising properties of this substance and the SCCP conclusion of opinion SCCP/1105/07 also stated concerns about this allergenic potential, only studies addressing this endpoint were considered.

3.1.1. Chemical identity

3.1.1.1. Primary name and/or INCI name

Phytonadione (INCI name)

3.1.1.2. Chemical names

1,4-naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, (r-*(r*,r*-e)))
2',3'-trans-vitamin K1
2-Methyl-3-[(min 80%E,7RS,11RS)-3,7,11,15-tetramethyl-2-hexadecenyl]-1,4-naphthoquinone
2',3'-trans-phylloquinone
α-phylloquinone
2-methyl-3-phytyl-1,4-naphthoquinone
phytylmenadione
3-phytylmenadione
phytomenadione
antihemorrhagic vitamin

3.1.1.3. Trade names and abbreviations

Aquamephyton konakion
combinal k1 mephyton
k-ject mono-kay
kativ n monodion
kephton synthex p
kinadion

3.1.1.4. CAS / EINECS number

Vitamin K1

<table>
<thead>
<tr>
<th>CAS</th>
<th>EINECS *</th>
</tr>
</thead>
<tbody>
<tr>
<td>84-80-0</td>
<td>201-564-2 (phytomenadione)</td>
</tr>
<tr>
<td>11104-38-4</td>
<td>234-330-3 (vitamin K1)</td>
</tr>
<tr>
<td>81818-54-4</td>
<td>279-833-9 (2-methyl-3-(3,7,11,15-tetramethylhexadec-2-ethyl)-1,4-naphthoquinone)</td>
</tr>
</tbody>
</table>

* The names in brackets refer only to the EINECS numbers
3.1.1.5. Structural formula

The formula indicates 2'-Trans-7R, 11R-stereoisomer

The Vitamin K1 molecule has two geometrical isomers (cis-trans or (Z)-(E) isomers) plus two asymmetric carbon atoms (C7 and C11), each generating two enantiomers (R or S). Thus, there are eight diastereoisomers (four in the *trans* and four in the *cis* configuration). The name Vitamin K is appropriate only for the 2'-Trans-7R, 11R-stereoisomer (the others are not vitamins), representing 12.5% in an equimolar mixture.

3.1.1.6. Empirical formula

Empirical formula: \( \text{C}_{31}\text{H}_{46}\text{O}_{2} \)

3.1.2. Physical form

Clear yellow to golden yellow viscous liquid

3.1.3. Molecular weight

Molecular weight: 450.68 g/mol

3.1.4. Purity, composition and substance codes

/

3.1.5. Impurities / accompanying contaminants

Commercial preparations may contain up to 20% of the biological inactive cis isomer.

Ref.: 1

Commerially available phytonadione (phylloquinone) is prepared synthetically and may contain not only 2',3'-trans-phylloquinone (not less than 75%), but also 2',3'-cis-phylloquinone and trans-epoxyphylloquinone (not more than 4.0 percent). Phyloquinone occurs in nature only as the 2', 3'-Trans-7R, 11R-stereoisomer.

Ref.: 2

HPLC chromatograms
Three chromatograms were provided without any explanation or identification of the peaks. After 5 minutes and one hour irradiation with UV, several new unidentified peaks appeared on the chromatograms, which were also not described. No information on the nature of UV exposure of the test substance was given.

3.1.6. Solubility

500 mg/l water (22 °C)
500 mg/l hydrochloric acid 0.1 N (22 °C)
500 mg/l sodium hydroxide 0.1 N (22 °C)
500 mg/l glycerine (22 °C)
4500 mg/l DMSO (dimethyl sulfoxide) (22 °C)
11000 mg/l methanol (22 °C)
15000 mg/l acetonitrile (22 °C)
75000 mg/l ethanol (22 °C)
1 g/l n-octanol, diethyl ether, acetone, benzene, ethyl acetate, dichloromethane, chloroform, n-hexane, cyclohexane, dioxane (22 °C)

3.1.7. Partition coefficient (Log P<sub>ow</sub>)

3.1.8. Additional physical and chemical specifications

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Melting point</td>
<td>approx. - 20 °C</td>
</tr>
<tr>
<td>Boiling point</td>
<td>140-145 °C</td>
</tr>
<tr>
<td>Density</td>
<td>0.97 g/cm³</td>
</tr>
</tbody>
</table>

3.1.9. Stability

Stable to air and moisture, but decomposes in sunlight. Unaffected by dilute acids, but is destroyed by solutions of alkali hydroxides and by reducing agents.

General Comments on physico-chemical characterisation

- The data provided on the physico-chemical characterisation of phytonadione is insufficient.
- No data was provided on 'phytonadione-oxide'
- It is not clear from the submission to which substance the term 'phytonadione-oxide' refers to. However, it possibly is phytonadione epoxide (CAS 25486-55-9, EINECS 247-022-9).

3.2 Function and use

Phytonadione (phyloquinone) is present in plant sources, especially green leafy vegetables. It is also present in small amounts in dairy products. It is synthesised by bacterial flora in the jejunum and ileum. The amount synthesised in the gut contributes significantly towards the daily requirement of the vitamin.

Vitamin K is involved in blood clotting, bone and kidney metabolism. Roles in cell signalling and brain lipid metabolism have also been proposed. Because vitamin K is widespread in the diet and provided by bacteria, deficiency is generally secondary to conditions such as malabsorption. Newborn babies have low levels of vitamin K, which may result in haemorrhagic disease of the newborn.

There may be decreased utilisation of the vitamin in the production of the vitamin K-dependent clotting factors during any form of acute or chronic liver disease. This is as a result of the destruction of the rough endoplasmic reticulum in the hepatocyte. Patients with hypoprothrombinaemia related to hepatic disorders usually respond to daily parenteral doses of 10 mg of vitamin K for three days. If no response to this treatment is noted this suggests serious hepatocellular damage (Basu and Dickerson, 1996).
The physiological activity of phylloquinone is based on its ability to change between its oxidized (quinone and 2,3-epoxide) and reduced (hydroquinone) forms. The major role of phylloquinone is the post-translational addition of a carboxyl-group into the γ-position of glutamate residues of specific proteins. In this respect, the prime physiological relevance of phylloquinone is the synthesis of coagulation proteins (Ferland, 1998; Olson, 1999 and 2000).

Whereas the vitamin K-dependent coagulation proteins are all synthesised in the liver, vitamin K is also essential for the synthesis of a number of proteins produced in extra-hepatic tissues. Examples of the latter group of proteins include:

- the bone Gla-protein, osteocalcin, which is exclusively synthesised by osteoblasts and odontoblasts, and which is a negative regulator of bone formation;
- matrix Gla-protein (MGP), which is synthesised in most soft tissues, but predominantly in cartilage (by chondrocytes) and in vessel wall (by vascular smooth muscle cells) and which is a potent inhibitor of soft tissue calcification;
- growth arrest-specific gene 6 protein (Gas6), which is a ligand for tyrosine kinases and has strong apoptotic activity in cultured cells.

Ref.: 5

Claimed uses for Vitamin K1 as a cosmetic include skin lightening, periorbital hyperpigmentation, treatment of actinic and traumatic purpura and treatment of bruising after laser treatment.

The SCCP is aware of cosmetic products on the market with Vitamin K1 concentrations as high as 8%.

The company that has submitted safety data for this evaluation declares that: "following AFSSAPS recommendations and our own observations...no product [...] contains Vitamin K since 1 January 2005". It also stated that from this date, an oxidised form of Vitamin K1 was used instead. No data was provided about the formula of oxidised Vitamin K1.

Ref.: 6

3.3. Toxicological Evaluation

3.3.1. Acute toxicity

3.3.1.1. Acute oral toxicity

No data submitted

3.3.1.2. Acute dermal toxicity

No data submitted

3.3.1.6. Acute inhalation toxicity

No data submitted
### 3.3.2 Irritation and corrosivity

#### 3.3.2.1 Skin irritation

No data submitted

#### 3.3.2.2 Mucous membrane irritation

No data submitted

### 3.3.3 Skin sensitisation

**Murine Local Lymph Node Assay (LLNA) for Vitamin K1**

**Guideline:** OECD 429  
**Species/strain:** CBA/J mouse, nulliparous and non-pregnant females.  
**Group size:** 7 groups of 4 animals  
**Test substance:** vitamin K  
**Batch:** 20040510  
**Purity:** 98.96% (full isomeric composition not clarified, % active ingredient unknown)  
**Concentrations:** 5, 10, 25, 50, 100% in acetone/olive oil (4/1; v/v)  
**Positive control:** α-hexylcinnamaldehyde (HCA)  
**GLP:** in compliance

**Results**

Vitamin K1 was non-irritant in the preliminary test. The highest concentration retained for the main test was the maximal practicable concentration (100%).

In the main test, twenty-eight female CBA/J mice were allocated to seven groups: five treated groups of four animals receiving the test item Vitamin K (isomeric mixture) at the concentration of 5, 10, 25, 50 or 100%, one negative control group of four animals receiving the vehicle (mixture acetone/olive oil (4/1; v/v)), one positive control group of four animals receiving alpha-hexylcinnamaldehyde (HCA) at the concentration of 25%.

**Proliferation assay**

No lymphoproliferation was noted at any of the test concentrations, while significant lymphoproliferation was observed with HCA at 25%.

The results are presented in the following table:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Concentration (%)</th>
<th>Irritation level</th>
<th>Stimulation Index (SI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test item 5</td>
<td>non-irritant</td>
<td>1.78</td>
<td></td>
</tr>
<tr>
<td>Test item 10</td>
<td>non-irritant</td>
<td>2.10</td>
<td></td>
</tr>
<tr>
<td>Test item 25</td>
<td>non-irritant</td>
<td>0.80</td>
<td></td>
</tr>
<tr>
<td>Test item 50</td>
<td>non-irritant</td>
<td>0.88</td>
<td></td>
</tr>
<tr>
<td>Test item 100</td>
<td>non-irritant</td>
<td>1.67</td>
<td></td>
</tr>
<tr>
<td>HCA 25</td>
<td>-</td>
<td>11.18</td>
<td></td>
</tr>
</tbody>
</table>
Conclusion
Under these experimental conditions, Vitamin K1 (isomeric mixture) did not induce delayed contact hypersensitivity in the murine Local Lymph Node Assay.

Ref.: 7

Murine Local Lymph Node Assay (LLNA) for Vitamin K hv (irradiated Vitamin K1)

Guideline: OECD 429
Species/strain: CBA/J mouse, nulliparous and non-pregnant females.
Group size: 7 groups of 4 animals
Test substance: vitamin K(hv)
Batch: 20040510
Purity: 98.96% (full isomeric composition not clarified, % active ingredient unknown)
Concentrations: 5, 10, 25, 50, 100% in acetone/olive oil (4/1; v/v)
Positive control: α-hexylcinnamaldehyde (HCA)
GLP: in compliance

Results
Vitamin K1 was non-irritant in the preliminary test. The highest concentration retained for the main test was the maximal practicable concentration (100%).

In the main test, twenty-eight female CBA/J mice were allocated to seven groups: five treated groups of four animals receiving the test item Vitamin K at the concentration of 5, 10, 25, 50 or 100%, one negative control group of four animals receiving the vehicle (mixture acetone/olive oil (4/1; v/v)), one positive control group of four animals receiving -hexylcinnamaldehyde (HCA), at the concentration of 25%.

Proliferation assay
No lymphoproliferation was noted at any of the test concentrations, while significant lymphoproliferation was observed with HCA at 25%.

The results are presented in the following table:

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Concentration (%)</th>
<th>Irritation level</th>
<th>Stimulation Index (SI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Test item</td>
<td>5</td>
<td>non-irritant</td>
<td>1.02</td>
</tr>
<tr>
<td>Test item</td>
<td>10</td>
<td>non-irritant</td>
<td>0.64</td>
</tr>
<tr>
<td>Test item</td>
<td>25</td>
<td>non-irritant</td>
<td>0.80</td>
</tr>
<tr>
<td>Test item</td>
<td>50</td>
<td>non-irritant</td>
<td>1.10</td>
</tr>
<tr>
<td>Test item</td>
<td>100</td>
<td>non-irritant</td>
<td>1.10</td>
</tr>
<tr>
<td>HCA</td>
<td>25</td>
<td>-</td>
<td>8.54</td>
</tr>
</tbody>
</table>

Conclusion
Under these experimental conditions, the test item Vitamin K hv did not induce delayed contact hypersensitivity in the murine Local Lymph Node Assay.

Ref.: 8

Comment
The batch and the analytical certificate provided was for the non-irradiated form of Vitamin K (isomeric mixture). No data about the isomeric composition of the test substance in both
tests are provided. Therefore, no conclusion can be made regarding the sensitising potential in the LLNA of vitamin K1, either irradiated or non-irradiated before use.

**Determination of allergenic and anaphylactogenic potential of KONAKION suspensions in guinea pigs**

Study on KONAKION mixed micelles ampoule formulation (Ro 01-6722/120) in comparison with commercial KONAKION ampoule formulation (Ro 01-6722/92) by two different induction procedures (i.v. and i.d.).

**Guideline:**

- Species/strain: Outbred Himalayan white spotted female guinea pigs
- Group size: 8
- Test substance: KONAKION mixed micelles ampoule formulation (Ro 01-6722/120)
  - Vitamin K1 (KONAKION, anhydrous) 10.0 mg
  - Glycolic acid 54.6 mg
  - NaOH 1 N 123.2 µl
  - PHOSPHOLIPON, anhydrous and ethanol free 75.6 mg
  - HCl 1N 10.0 µl
  - NaOH 0.1 N ad pH 6.0 q.s.
  - H₂O injectable grade ad 1.0 ml

KONAKION mixed micelles ampoule formulation (Ro 01-6722/120)
- Vitamin K1 (KONAKION, anhydrous) 10.5 mg
- Phenol, crist. 5.0 mg
- CREMOPHOR EL 40.0 mg
- Propylene glycol 20.0 mg
- H₂O injectable grade ad 1.0 ml

- Batch: /
- Purity: /
- Concentrations: 1%
- Positive control: /
- GLP: /

The study compared the sensitisation potential in Guinea pigs of two Konakion formulations (10 mg vitamin K1/ml mixed micelles formulation and 10.5 mg vitamin K1/ml commercial cremophor EL containing formulation) given for induction either i.v. or i.d.. The respective control groups received NaCl-solution. There were 8 animals per group.

Induction by the i.v. route consisted of total 4 injections of 4 or 2 ml/kg of undiluted test material once a week for four weeks. For induction by the i.d. route animals received totally 10 intradermal inductions of 0.1 ml of undiluted test material 3 times a week.

Two challenges were performed all by i.d. route with 2 suitable dilutions: 1:100 and 1:300 for the mixed micelles formulation and 1:30 and 1:100 for the commercial cremophor EL formulation. The first challenge was given 2 weeks after the last induction treatment and the second after a further two weeks. Elicitation was performed 2 weeks after the second challenge by i.v. application at the same dose as used in the i.v. induction phase.

**Results**

With the mixed micelles formulation no reaction was observed in the challenge and in the elicitation phase independent whether induction was performed by the i.v. or the i.d. route. With the commercial formulation containing cremophor EL (PEG-35 Castor Oil) there was a positive challenge test after i.d. induction but not after i.v. induction. Positive i.v. elicitation reactions were observed after both i.d. and i.v. induction with the cremophor EL formulation. 2 animals died about 20 minutes after starting the injections.

Ref.: 21
Determination of anaphylactogenic potential of KONAKION mixed micelles ampoules Ro 01-6722/120 in guinea pigs.

Guideline: /  
Species/strain: Outbred Himalayan white spotted female guinea pigs  
Group size: 8  
Test substance: KONAKION mixed micelles ampoule formulation (Ro 01-6722/120)  
Vitamin K1 (KONAKION, anhydrous) 10.5 mg  
Phenol, crist. 5.0 mg  
CREMOPHOR EL 40.0 mg  
Propylene glycol 20.0 mg  
H2O injectable grade ad 1.0 ml  
Batch: /  
Purity: /  
Concentrations: 1%  
Positive control: /  
GLP: /  

The anaphylactogenic potential of Konakion Ro 01-6772/120 (mixed micelles formulation containing 10 mg vitamin K1/ml) was investigated in female guinea pigs with induction either by i.v. or i.d. application. Induction by the i.v. route consisted of total 4 injections of 3 ml/kg of undiluted test material once a week for four weeks. For induction by the i.d. route animals received totally 10 intradermal inductions of 0.1 ml of undiluted test material over a period of 22 days. Control groups received physiological saline.

Two challenges were performed all by i.d. route with a 1:10 dilution of the test material. The first challenge was given 2 weeks after the last induction treatment and the second after further two weeks. Elicitation was performed 2 weeks after the second challenge by i.v. application at the same dose as used in the i.v. induction phase (3 ml/kg).

Results
In the test group which received intravenous induction and elicitation at a dose level of 3 ml/kg one animal showed clinical signs indicative of anaphylaxis at elicitation. No responses were noted in the control group. In the test group which received intradermal induction using undiluted test material followed by intravenous elicitation at a dose level of 3 ml/kg, 2 animals showed clinical signs indicative of anaphylaxis at elicitation. No responses were noted in the control group.

The authors conclude that Konakion RO 01-6722/120 may produce anaphylactoid responses following both intravenous and intradermal induction procedures. The results of cross tests indicate that not only the vehicle, which contains cremophor and propylen-glycol, but also the active compound KONAKION may play a certain role in connection with the side effects. This was confirmed by the INVERESK study with Ro 01-6722/120, since the second skin test was slightly positive and some animals showed weak systemic anaphylactogenic reactions after intravenous administration of the test material.

Ref: 22

Comments
These two studies are old and explore a type of allergic reaction, i.e. anaphylactadic potential by i.v. or i.d. route, which is quite different from contact hypersensitivity. They are performed with preparations containing several ingredients and not with Vitamin K1 itself. They show that the type of preparation may influence the rate of sensitisation but that Vitamin K1 itself can induce immune response in experimental animals.
### 3.3.4. Dermal / percutaneous absorption

No data submitted

### 3.3.5. Repeated dose toxicity

#### 3.3.5.1. Repeated Dose (28 days) oral / dermal / inhalation toxicity

No data submitted

#### 3.3.5.2. Sub-chronic (90 days) oral / dermal / inhalation toxicity

No data submitted

#### 3.3.5.3. Chronic (> 12 months) toxicity in mice

No data submitted

### 3.3.6. Mutagenicity / Genotoxicity

#### 3.3.6.1. Mutagenicity / Genotoxicity in vitro

No data submitted

#### 3.3.6.2. Mutagenicity / Genotoxicity in vivo

No data submitted

### 3.3.7. Carcinogenicity

No data submitted

### 3.3.8. Reproductive toxicity

#### 3.3.8.1. One generation reproduction toxicity

No data submitted

#### 3.3.8.2. Teratogenicity

No data submitted

### 3.3.9. Toxicokinetics

No data submitted
3.3.10. Photo-induced toxicity

3.3.10.1. Phototoxicity / photoirritation and photosensitisation

**In vitro assessment of phototoxic potential using human reconstructed epidermis**

| Guideline: | / |
| Tissue: | human reconstitute d epidermis [SKINETHIC™] |
| Nº of chambers: | 6 |
| Test substance: | vitamin K1 phytonadione |
| Batch: | 03.581 |
| Purity: | / |
| Concentrations: | 100% and diluted to 10 and 1% in paraffin oil |
| GLP: | / |

A toxicity assay was carried out using SKINETHIC cultures (0.63 cm² epidermis). The test product was tested as supplied (i.e., 100%) and diluted to 10 and 1% (v/v) in paraffin oil. Reconstituted epidermis (REp) was treated overnight (approximately 18h). The toxic effect was assessed by using the MTT assay. No significant cytotoxicity was observed in epidermis. Taking into account these results, the test substance was to be applied undiluted on the culture surface, for a 24h incubation period prior to UV exposure.

Test product (6.3µl /epidermis) was applied directly onto the surface of tissues. Control and treated REps were incubated at 37°C for 24 hr and subsequently washed with HBSS. REps were irradiated with UV, dose 6 J/cm² (3 biopsies/UV, dose), while 2 REps of each experimental group were kept at room temperature in the dark during UVA exposure (dark control). After further incubation at 37°C for 24h, viability was assessed by a MTT test.

**Results**

| OD₅₇₀ (mean) | 0 | 6 J/cm² | 0 | 6 J/cm² |
| St. Dev. | 0.899 | 0.005 | 0.871 | 0.008 |
| Viability | 100% | 97% | 100% | 38% |
| Cytotoxicity | 3% | 62% |

**Conclusion**

Vitamin K1 (phytonadione) can be considered as phototoxic in vitro. Ref.: 9

**Comments**

In this study, no positive controls were used. The isomeric composition of the test compound was not reported.

The method which was used is not a validated in vitro method for the assessment of phototoxic potential. The 3T3 NRU Phototoxicity test (OECD 432) should have been used instead.

3.3.10.2. Phototoxicity / photomutagenicity / photoclastogenicity

No data submitted
3.3.11. Human data

Repeated Insult Patch Test with consumer product (US GCP 2005),

A semi-occlusive patch test with an eye cream (NeoStrata bionic eye cream) containing 1% Vitamin K1 (DSM quality) on the upper back was conducted with 114 (14 did not complete the study) healthy volunteers. The patches with the test product were applied three times a week for a total of 9 applications in the induction phase followed by a challenge patch two weeks later. Patches were removed after 24 hours, and the sites were scored immediately before re-application during induction and in the challenge phase 24 and 72 hours after application.

The challenge test sites in all individuals were scored zero. Under the conditions of the study the tested eye cream did not indicate a clinically significant potential for dermal irritation or allergic contact sensitisation.

Ref.: 23

Patch tests with two isomers of Vitamin K were applied on the back of 107 healthy volunteers. No reaction was observed after 48 and 72 hours (only statement, no data provided).

Ref.: 10

Comment

References 11 and 12 describe a therapeutic use of vitamin K and were considered not relevant for risk assessment.

There have been unspecified adverse skin reactions reported from the topical use of vitamin K containing products (6 case reports in France, 2 in Belgium, 1 in Spain and 1 in Italy). The product manufacturer considered these adverse reactions to be secondary to the use of the products on injured skin, which is not recommended. The estimated frequency was 2.5 to 4 cutaneous intolerance for 100 000 sold products (Vitamin K1, 1 and 2%).

Ref.: 13

The French authorities, in a report of the Commission de cosmétologie, noted 11 cases of adverse effects after topical application of Vitamin K1 containing products in France, including the 6 cases reported in the cosmetovigilance report from the manufacturer (Ref. 13). Amongst these, two cases were reported with products containing oxidised Vitamin K1.

Ref.: 14

Contact dermatitis due to topical cosmetic use of Vitamin K1

A 27-year-old woman developed dermatitis of the face, particularly in the periorbital area. For 4 months, she had used a cosmetic treatment of the face to decrease periorbital hyper-pigmentation, Auriderm K2® cream, a mixture containing vitamin K1 and retinol. Patch tests showed a positive reaction to Auriderm K2® cream. Patch tests with the ingredients of the cosmetic cream were positive to vitamin K1 2% pet. (D2+/ D3++) and trans-vitamin K 2% pet (D2+/D3+++).

This was the first report of allergic contact dermatitis due to vitamin K1 from topical cosmetic use.

Ref.: 17

A 45 year old woman developed a severe eczematous reaction on her face where she had been applying a clarifying cream. A repeated open application test (ROAT) on her forearm was
positive. Patch testing of the cream’s ingredients showed positive reactions to vitamin K1. At 1% and 10% in petrolatum; controls were negative.

Ref.: 16

2 cases of eyelid dermatitis caused by Vitamin K1 in a cosmetic cream (Ureadin® facial contour) were reported in women using the cream for 3-4 weeks. Patch tests to the Ureadin® cream (+++) and Vitamin K1 (+++) were positive but the cream without the vitamin was negative; 15 control subjects showed no reactions. The patch test preparation of vitamin K1 was 1 mg/ml aqueous.

Ref.: 20

**Eczematous hypersensitivity from aqueous vitamin K injection**

A case was reported of an eczematous reaction following injection with vitamin K1 for treatment of warfarin-induced hypoprothrombinemia.

Ref.: 18

**Type IV hypersensitivity to vitamin K**

The day after intramuscular injection of vitamin K1 (phytomenadione) into her thigh, a 27-year-old-woman with normal liver function developed a relapsing and remitting eczematous reaction localized to the injection site, and later a further eczematous reaction under an adhesive dressing (Duoderm®). On patch testing, she was positive to vitamin K1 and cross-reacted to vitamin K4; she was also positive to colophonium and to ester gum rosin, the dressing adhesive. Recurrent angio-oedema persisted for several months and, 2 years later, symptoms were still occurring over the injection sites. Structure-activity relationships among vitamin K allergens are discussed.

Ref.: 19

Between 1964 and 1994, at least 52 patients with cutaneous adverse effects of vitamin K were described in the European and North American literature, with 94 cases in the Japanese literature. A review of the details of these patients, primarily from therapeutic use of Vitamin K1, is given and 2 new therapeutic use cases reported. Adverse effects were seen not only in patients with liver-function disturbances but also in patients without liver diseases, and occur mostly after intramuscular or subcutaneous administration of vitamin K1, independent of the total dose. Patch and intracutaneous tests often give positive reactions. The mechanism of action was considered in many patients to be a delayed-type hypersensitivity reaction.

**Intramuscular and subcutaneous injections** of Vitamin K1 have induced three types of cutaneous reactions:

- 10-14 days after injection eczematous reactions. The allergic mechanism was confirmed in several patients by intradermal and/or epicutaneous testing. There were positive patch test reactions with Vitamin K1; Vitamin K3 was negative.
- Scleroderma-like patches at site of former injection several months or year after injection. Sensitization was proven in 4 patients by intradermal tests.
- Urticaria

Additionally, 5 individuals exposed to vitamin K1 in the occupational setting and who developed contact dermatitis on their hands and faces are recorded.

Ref.: 15

### 3.3.12. Special investigations

No data submitted
3.3.13. Safety evaluation (including calculation of the MoS)

Not applicable

3.3.14. Discussion

There are a number of clinical case reports concerning cutaneous sensitisation to Vitamin K1.

The two studies in the current dossier concerning this endpoint are old and explore a type of allergic reaction i.e. anaphylactic potential by i.v. or i.d. route, which is quite different from contact hypersensitivity. They are performed with preparations containing several ingredients and not with Vitamin K1 itself. However, they show that Vitamin K1 itself can induce immune response in experimental animals.

The negative human HRIPT performed with an eye cream is not relevant to the question of allergenicity of Vitamin K itself. Although the risk of allergy to this substance might be small, it has to be considered that Vitamin K1 can be a life-saving therapeutic agent. In cases of pre-existing sensitisation caused by topical application of Vitamin K1 in cosmetics, an individual might not be able to receive Vitamin K1 therapeutically.

4. CONCLUSION

The studies provided on the allergenic potential of Vitamin K1 did not supersede the concerns stated in opinion SCCP/1105/07.

The SCCP maintains the view that use of Vitamin K1 in cosmetic products is not safe, since it may cause cutaneous allergy and individuals so affected may be denied an important therapeutic agent.

5. MINORITY OPINION

Not applicable

6. REFERENCES

References taken from SCCP/1105/07

7. Sire G. Vitamin K. Evaluation of skin sensitization potential in mice using the local lymph node assay. CIT, France. Study number 31769 TSS, 26 January 2007
14. Avis de la Commission de cosmetology n° 25. France. 29 September 2005
17. Veneziano L., Simonetta S., Voudouris S., Tosti A. Contact dermatitis due to topical use of vitamin K. Contact Dermatitis 2005. 52(2), 113-114

References included in submission of November 2007

23. Richard Eisenberg: Consumer Products Tested Co for NeoStrata Company Inc, Repeated Insulted Patch Test on 101 healthy volunteers for an Eye Cream product containing 1% Vitamin K1, December 19, 2005